Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487311 | 0.90 | RAB9A (0.49) | ALDH1A1KDM4EMAPK1RAB9A | |
| SCHEMBL12030423 | 0.88 | RAB9A (0.51) | ALDH1A1KDM4EMAPK1RAB9A | |
| SCHEMBL2485150 | 0.81 | GSK3B (0.44) | ALDH1A1KDM4EMAPK1DGAT1RAB9A | |
| SCHEMBL13345625 | 0.79 | CKS1B (0.47) | KDM4EDGAT1SMN1; SMN2 | |
| SCHEMBL12030415 | 0.79 | RAB9A (0.49) | ALDH1A1KDM4EMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL23413438 | 0.77 | ALDH1A1 (0.75) | ALDH1A1KDM4EMAPK1DGAT1SMN1; SMN2 | |
| SCHEMBL3615928 | 0.77 | PPARG (0.40) | ALDH1A1KDM4EMAPK1DGAT1 | |
| SCHEMBL596762 | 0.75 | TARBP2 (0.52) | ALDH1A1KDM4EDGAT1RAB9ASMN1; SMN2 | |
| SCHEMBL3611262 | 0.75 | IKBKB (0.50) | ALDH1A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL2879336 | 0.75 | IKBKB (0.50) | ALDH1A1KDM4EDGAT1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492401-B2 | Thiazolopyridine sirtuin modulating compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492401-B2 | Thiazolopyridine sirtuin modulating compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492401-B2 | Thiazolopyridine sirtuin modulating compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS (US) | 2013-04-04 | — | — | US | disclosed |
| US-8343997-B2 | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343997-B2 | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343997-B2 | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC., | 2011-12-15 | — | — | US | disclosed |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC., | 2011-12-15 | — | — | US | disclosed |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC., | 2011-12-15 | — | — | US | disclosed |
| EP-2376502-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | Sirtris Pharmaceuticals, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071853-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071853-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | ALDH1A1 722/4885KDM4E 2933/4885MAPK1 1145/4885 |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | ALDH1A1 722/4885KDM4E 2933/4885MAPK1 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.